BostonGene logo

Waltham, Mass • 2025-08-12

BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay

Study Confirms Regulatory-Grade Performance and AI-Driven Clinical Utility to Advance Precision Oncology and Patient Stratification for Drug Development

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, “Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort,” in Communications Medicine, a high-impact journal in the Nature portfolio. The study underscores the BostonGene Tumor Portrait™ assay as a clinically robust, regulatory-grade platform that forms the foundation of BostonGene’s AI-powered platform, purpose-built for precision oncology and designed to accelerate therapeutic development and enhance clinical data collection.

The Tumor PortraitTM assay integrates DNA and RNA sequencing into a single end-to-end test, delivering a multimodal view of each tumor.  Approved under CLIA, CAP and the New York State Department of Health, the platform enhances patient stratification, predictive biomarker discovery and clinical trial enrollment–all critical to reducing the risks associated with drug development and improving clinical trial success rates.

The study details the implementation of highly stable clinical RNA-seq protocol, deployed in ready-to-use clinical settings and tested across more than 2,200 tumors, demonstrating high reproducibility, strong clinical actionability (98% of cases) and advanced detection of alterations, fusions, immune signatures, tumor microenvironment profiles and AI-based predictive classifications.

“Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development,” said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. “By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding of the tumor microenvironment and genetics, smarter patient selection and more confident, data-driven decisions throughout the drug development lifecycle. This validation sets a new benchmark for translational research and diagnostic innovation.”

About BostonGene Corporation

BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.
Erin Keleher

Erin Keleher

Senior Director

+1-617-283-2285

[email protected]